Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis
Henrik H. Hansen, Susanne Elisabeth Pors, M Andersen, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11

Showing 11 citing articles:

Anti-inflammatory benefits of semaglutide: State of the art
Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100340-100340
Open Access | Times Cited: 12
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients
Ernest Adeghate
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 3, pp. 223-232
Open Access | Times Cited: 4
Glucagon-like peptide-1 receptor agonism and end-organ protection
Samuel J. Daniels, Cecilia Karlsson, Patrick Schrauwen, et al.
Trends in Endocrinology and Metabolism (2025)
Open Access
Navigating Metabolic Challenges in Ovarian Cancer: Insights and Innovations in Drug Repurposing
Sara Mikhael, Georges Daoud
Cancer Medicine (2025) Vol. 14, Iss. 4
Open Access
The multifaceted role of agents counteracting metabolic syndrome: A new hope for gastrointestinal cancer therapy
Elena Crecca, Gianfranco Di Giuseppe, C Camplone, et al.
Pharmacology & Therapeutics (2025), pp. 108847-108847
Closed Access
Protective Effects of Hepatocyte Stress Defenders, Nrf1 and Nrf2, against MASLD Progression
May G. Akl, Lei Li, Scott B. Widenmaier
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8046-8046
Open Access | Times Cited: 3
Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity
Isidora Stanisavljević, Sladjana Pavlović, Bojana Simović Marković, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 181, pp. 117668-117668
Closed Access | Times Cited: 2
Current and emerging strategies for the prevention of hepatocellular carcinoma
Yee Hui Yeo, Manal F. Abdelmalek, Seema A. Khan, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 22, Iss. 3, pp. 173-190
Closed Access | Times Cited: 2
Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction–associated steatohepatitis
Junyan Lyu, Hikari Okada, Hajime Sunagozaka, et al.
Hepatology Communications (2024) Vol. 8, Iss. 5
Open Access | Times Cited: 1
Semaglutide interferes with postnatal growth in a diet-dependent manner
Amélie Joly, Lucas Rebiffé, Yves Dusabyinema, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors
Nutan Sharma, Lakhwinder Singh, Aditya Sharma, et al.
Pharmacological Research (2024) Vol. 208, pp. 107375-107375
Open Access
Anti-Diabetic Therapies and Cancer: From Bench to Bedside
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela, et al.
Biomolecules (2024) Vol. 14, Iss. 11, pp. 1479-1479
Open Access
Page 1

Scroll to top